Prism Research Selects OmniComm Systems' TrialOne Suite to Automate Phase I Clinic Operations
OmniComm Systems, Inc., a company in the EDC marketplace, today announced that its TrialOne® suite of applications has been chosen by Prism Research to automate their clinical trial operations and processes within their early phase clinic.
TrialOne® is a web-based, mobile, clinic automation solution designed specifically for early-phase research to facilitate recruitment, appointment scheduling, study building and design, screening, source data capture, sample tracking and reporting. TrialOne® offers time-based data entry and integration with bar-code scanners and printers as well as biomedical monitoring devices to automate data, sample collection and processing. Additionally, TrialOne’s import and export features provide integration with LIM systems for lab orders and results processing as well as full SAS export capability including support of SDTM domains.
“Traditionally, implementing solutions for Phase I clinics has been difficult, time-consuming and cost prohibitive,” said Stephen Johnson, President and COO of OmniComm. “Most offerings today do not work well for these fast-paced clinics who demand instantaneous and reliable solutions. In the past, clinics have had to resort to localized solutions and manage the IT infrastructure internally. Implementations took up to a year and were extremely complex and resource intensive. With our Software-as-a-Service approach, the entire process from kickoff to production for this implementation will be less than 6 months.”
OmniComm offers a turnkey, hosted solution and a Quick Start validation package that facilitates and expedites the entire implementation process. Clinics can centralize their installation in OmniComm’s world-class data center and back-up facilities without the costly infrastructure and overhead of additional staff and software upgrades.
Prism Clinical Research is a Phase I-IV, 52-bed, clinical trial site located in the heart of the Minneapolis / St. Paul metropolitan area that specializes in complex, phase I and phase IIA clinical trials. In addition to healthy volunteer studies, Prism Clinical Research possesses a diverse, volunteer database of numerous disease states.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
